Vilon Dosage, Reconstitution & Mixing Trends

Explore vilon calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized vilon calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What Vilon Is

Vilon is a synthetic Lys-Glu (KE) dipeptide from the Russian Khavinson short-peptide program, sourced mainly for immune-aging and gerontology research. It ships as a lyophilized powder you reconstitute before use, so the real difference between vendors is what the certificate of analysis (COA) actually shows.

In the Khavinson framework, Vilon is proposed to act through direct binding to gene-promoter DNA in thymic epithelial cells and peripheral lymphocytes, selectively modulating transcription of genes involved in T-cell differentiation, chromatin organisation, and cellular senescence.[2][3] This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.

Russian observational cohorts have reported Vilon (often paired with Thymalin) in elderly immune-decline contexts, with reported improvements in T-cell subset distributions and lymphocyte chromatin-condensation markers; the Lezhava/Khavinson 2004 Bull Exp Biol Med paper is the most-cited specific finding, describing chromatin-decondensation effects on old-age lymphocytes after exposure to Vilon and Livagen.[3][4] No Western Phase 2 or 3 trial has been registered.

Used in Russia as an approved immune-modulatory preparation. Not FDA-approved or EMA-authorised; sold elsewhere as research-grade material.

Vilon Research Sources

Vilon Dosing Context

Vilon has a reported half-life of ~30 min (short-peptide estimate). The pharmacokinetic reference models an interval of once daily (in 10–20 day courses); this is not a measured community cadence or a dosing recommendation. This Khavinson dipeptide (Lys-Glu) clears from plasma within an hour with no buildup; its effect is thought to come from the course as a whole rather than a steady level. Pharmacokinetic source: No published human PK; Khavinson short-peptide bioregulator estimate. It is catalogued under Anti-Aging Peptides on WPA.

Vilon Community Calculator Data

22 Vilon reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

Vilon Research Background and Calculator Data

Vilon (Lys-Glu, a synthetic dipeptide) is one of the original short-peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson, the Russian gerontologist whose decades-long research program built the conceptual framework now collectively known as the Khavinson short-peptide bioregulators. The Khavinson hypothesis — developed across hundreds of Russian-language publications and a smaller English-language record — proposes that very short oligopeptides extracted from young animal tissues, or chemically synthesized to match those sequences, exert organ-specific epigenetic regulation by binding to gene-promoter regions and modulating transcription in the same tissue type they were originally derived from. Vilon's position in that framework is as a thymic / immune bioregulator, with the published Khavinson-group work reporting effects on CD4+/CD8+ T-cell ratios, IL-2 production, and chromatin decondensation in lymphocytes from elderly donors — the latter the basis of the broader Khavinson claim that short peptides can partially restore the heterochromatin compaction patterns that drift with cellular aging. The most-cited single experimental result in the Vilon literature is the Anisimov et al. (2001) lifespan-extension work in tumor-prone CBA mice, in which Vilon-treated animals showed both extended median lifespan and reduced spontaneous tumor incidence relative to controls. Vilon should be distinguished mechanistically from Thymalin (a multi-peptide thymic extract from the same Khavinson program, conceptually upstream of the synthetic dipeptide) and from Thymulin / FTS (a zinc-dependent nonapeptide isolated by Bach and Dardenne in Paris in 1977 — a different research program entirely, with a different mechanism). Vilon holds no FDA or EMA approval, and the controlled clinical literature outside the Russian-language Khavinson corpus is essentially absent.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.